WA
COGT icon

Whipplewood Advisors’s Cogent Biosciences COGT Stock Holding History

Whipplewood Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$423 – 722
2026
Q1 		$423 Buy
+11
New +$406 ﹤0.01% 989

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Whipplewood Advisors's COGT Position: Q2 2026 in Review

Whipplewood Advisors sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 11 shares — an estimated $423 sold.

Whipplewood Advisors first reported a position in COGT in Q1 2026 and held it in 1 quarter. The position peaked at $423 in Q1 2026. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Whipplewood Advisors reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
  • Whipplewood Advisors sold 11 Cogent Biosciences shares in Q2 2026, an estimated $423.
  • Whipplewood Advisors first reported a position in Cogent Biosciences in Q1 2026 and held it in 1 quarter.
  • Whipplewood Advisors's Cogent Biosciences position peaked at $423 in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.